IN2012DN01954A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01954A
IN2012DN01954A IN1954DEN2012A IN2012DN01954A IN 2012DN01954 A IN2012DN01954 A IN 2012DN01954A IN 1954DEN2012 A IN1954DEN2012 A IN 1954DEN2012A IN 2012DN01954 A IN2012DN01954 A IN 2012DN01954A
Authority
IN
India
Prior art keywords
partially processed
amount
bont
unprocessed
solution
Prior art date
Application number
Inventor
Harold V Taylor
Karl-Heinz Eisele
Cornelia Brunn
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41466928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN01954(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of IN2012DN01954A publication Critical patent/IN2012DN01954A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96419—Metalloendopeptidases (3.4.24)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is concerned with tools for the quality control and safety during manufacture of neurotoxins. In particular, it relates to a method for the determination of the amount of partially processed and/or unprocessed Botulinum neurotoxin A polypeptide (BoNT/A) in a solution comprising processed and partially processed and/or unprocessed BoNT/A comprising the steps of contacting a sample of said solution with a capture antibody which specifically binds to the partially processed and unprocessed BoNT/A under conditions which allow for binding of said antibody to said partially processed and unprocessed BoNT/A, whereby a complex is formed, and determining the amount of the formed complex, whereby the amount of the complex is indicative for the amount of the partially processed and/or unprocessed BoNT/A in said solution. Moreover, the present invention contemplates a device and a kit for carrying out said method.
IN1954DEN2012 2009-10-21 2010-10-18 IN2012DN01954A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27945309P 2009-10-21 2009-10-21
EP09173612 2009-10-21
PCT/EP2010/065618 WO2011048044A1 (en) 2009-10-21 2010-10-18 System for determining unprocessed and partially processed neurotoxin type a

Publications (1)

Publication Number Publication Date
IN2012DN01954A true IN2012DN01954A (en) 2015-08-21

Family

ID=41466928

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1954DEN2012 IN2012DN01954A (en) 2009-10-21 2010-10-18

Country Status (15)

Country Link
US (2) US8841080B2 (en)
EP (1) EP2491384B1 (en)
JP (1) JP5709877B2 (en)
KR (1) KR101788340B1 (en)
CN (1) CN102597769B (en)
AU (1) AU2010309932B2 (en)
BR (1) BR112012009436A2 (en)
CA (1) CA2773478C (en)
ES (1) ES2449303T3 (en)
IL (1) IL218455A (en)
IN (1) IN2012DN01954A (en)
MX (1) MX2012004454A (en)
PT (1) PT2491384E (en)
RU (1) RU2545825C9 (en)
WO (1) WO2011048044A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0513850A (en) 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa therapeutic composition with a botulically neurotoxin
RU2549463C1 (en) * 2013-12-03 2015-04-27 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) Method of determining botulinum neurotoxin of type a based immunodetection, combined with polymerase chain reaction
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2340299A (en) * 1998-01-26 1999-08-09 University Of Massachusetts Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
US6667158B1 (en) * 1998-12-17 2003-12-23 The United States Of America As Represented By The Secretary Of The Army Antibodies against type a botulinum neurotoxin
CA2371279A1 (en) 1999-05-12 2000-11-16 Leonard A. Smith Recombinant vaccine against botulinum neurotoxin
US20080171347A1 (en) * 2003-04-11 2008-07-17 Atassi M Zouhair Determining and reducing immunoresistance to botulinum toxin therapy using botulinum toxin a peptides
FR2869908B1 (en) * 2004-05-05 2006-07-28 Pharmaleads PEPTIDE SUBSTRATE RECOGNIZED BY BOTULINUM TOXIN TYPE A, BONT / A AND ITS USE IN DETECTING AND / OR DOSING THIS TOXIN OR INHIBITORS OF ITS ACTIVITY
CN100575363C (en) * 2007-03-07 2009-12-30 中国人民解放军军事医学科学院微生物流行病研究所 Human-derived anti-botulinum neurotoxin type A genetically engineered antibody and its preparation method and use
US7732579B2 (en) 2007-06-13 2010-06-08 The United States Of America As Represented By The Secretary Of Agriculture High-affinity monoclonal antibodies for botulinum toxin type A
JP5795539B2 (en) * 2009-02-19 2015-10-14 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー Means and methods for producing high purity neurotoxins
CN101503472B (en) * 2009-03-17 2011-08-10 中国人民解放军军事医学科学院生物工程研究所 Human source neutralizing antibody specific against botulinum neurotoxin type A and use thereof

Also Published As

Publication number Publication date
RU2545825C2 (en) 2015-04-10
US20120214182A1 (en) 2012-08-23
US8841080B2 (en) 2014-09-23
MX2012004454A (en) 2012-05-22
CA2773478A1 (en) 2011-04-28
JP5709877B2 (en) 2015-04-30
US20140349322A1 (en) 2014-11-27
RU2012120572A (en) 2013-11-27
ES2449303T3 (en) 2014-03-19
CN102597769B (en) 2014-11-05
KR101788340B1 (en) 2017-10-19
CN102597769A (en) 2012-07-18
IL218455A (en) 2015-10-29
EP2491384B1 (en) 2013-12-04
PT2491384E (en) 2014-02-21
JP2013508701A (en) 2013-03-07
RU2545825C9 (en) 2015-06-20
US9213026B2 (en) 2015-12-15
KR20120102639A (en) 2012-09-18
WO2011048044A1 (en) 2011-04-28
CA2773478C (en) 2018-07-17
HK1173493A1 (en) 2013-05-16
BR112012009436A2 (en) 2017-02-21
AU2010309932A1 (en) 2012-04-05
AU2010309932B2 (en) 2015-04-16
EP2491384A1 (en) 2012-08-29
IL218455A0 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
MX360513B (en) Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells.
UA95958C2 (en) Antibody that binds to cd22, immunoconjugates and uses therefor
NZ609824A (en) Immunochromatography devices, methods and kits
WO2008081849A1 (en) Method for quantification of peptide and protein
PT2185937E (en) Method for assaying sepsis in humans
WO2010091182A3 (en) Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
EA200802169A1 (en) METHODS OF ANALYSIS OF LANTHANE HYDROXYCARBONATE
WO2012035296A3 (en) Assay for prions
NZ602056A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2011011045A (en) Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities.
IN2012DN03911A (en)
MX2010005377A (en) A method for characterization of a recombinant polyclonal protein.
WO2010014854A3 (en) Antibodies that neutralize botulinum neurotoxins
GB201014028D0 (en) In-situ reagent
WO2010135574A3 (en) Systems and methods for determining the percentage of glycated hemoglobin
ATE438856T1 (en) BIOMARRKERS FOR Ovarian CANCER: PROTEINS RELATED TO CTAP3
WO2008112258A3 (en) Modified proteases
WO2009024726A3 (en) Method for purifying or detecting a target protein
WO2012164525A3 (en) Aging biomarkers
IN2012DN01954A (en)
EA201171178A1 (en) DEVICE AND METHOD FOR DETERMINATION AND QUANTITATIVE ANALYSIS OF ANALYSIS, IN PARTICULAR, MYCOTOXINS
MX2017011195A (en) Methods for enhancing the specific uptake of botulinum neurotoxins into cells.
DK2118666T3 (en) Method of normalizing the concentration of analytes in a urine sample
WO2012077139A8 (en) Method for the diagnosis of a carcinoma and uses thereof
MX2009008525A (en) The quantitative determination of risedronate in urine by spe-lc-ms-ms.